Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;33(1):65-72.
doi: 10.5581/1516-8484.20110017.

Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

Belinda Pinto Simões  1 , José Wilson Ramos Braga Junior, Maria Aparecida do Carmo Rego, Cármino Antônio de Souza
Affiliations

Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

Belinda Pinto Simões et al. Rev Bras Hematol Hemoter. 2011.

Abstract

Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results.

Keywords: Antineoplastic agents/administration & dosage; Drug monitoring, neoplasm; Drug resistance; Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy; Monitoring; Prognosis; Pyrimidines/therapeutic use; Receptor Protein-Tyrosine Kinases.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: JWRBS and MACR are employees of Bristol-Meyers Squibb, Brazil

This article was written with the support of Bristol-Myers Squibb

References

    1. Sawyers CL.Chronic myeloid leukemia N Engl J Med 1999340 (17): 1330-1340Comment in: N Engl J Med. 1999;341 (10):765 - PubMed
    1. Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE.Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations Cancer 2009115 (7): 1381-1394 - PubMed
    1. Redaelli A, Bell C, Casagrande J, Stephens J, Botteman M, Laskin B, et al. Clinical and epidemiologic burden of chronic myelogenous leukemia Expert Rev Anticancer Ther 20044 (1): 85-96 - PubMed
    1. O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 2003348 (11): 994-1004Comment in: Curr Hematol Rep. 2004;3(1):37-8. N Engl J Med. 2003; 348(11): 1048-50. Clin Lab Haematol. 2005;27(6):416-7 - PubMed
    1. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP.International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 2003349 (15): 1423-1432Comment in: N Engl J Med. 2003;349 (15): 1399-401 - PubMed

LinkOut - more resources